193 related articles for article (PubMed ID: 29695174)
1. Preparation of psoralen polymer-lipid hybrid nanoparticles and their reversal of multidrug resistance in MCF-7/ADR cells.
Huang Q; Cai T; Li Q; Huang Y; Liu Q; Wang B; Xia X; Wang Q; Whitney JCC; Cole SPC; Cai Y
Drug Deliv; 2018 Nov; 25(1):1056-1066. PubMed ID: 29695174
[TBL] [Abstract][Full Text] [Related]
2. Polymer-lipid hybrid nanoparticles: A novel drug delivery system for enhancing the activity of Psoralen against breast cancer.
Du M; Ouyang Y; Meng F; Zhang X; Ma Q; Zhuang Y; Liu H; Pang M; Cai T; Cai Y
Int J Pharm; 2019 Apr; 561():274-282. PubMed ID: 30851393
[TBL] [Abstract][Full Text] [Related]
3. Fabrication of psoralen-loaded lipid-polymer hybrid nanoparticles and their reversal effect on drug resistance of cancer cells.
Yuan Y; Chiba P; Cai T; Callaghan R; Bai L; Cole SPC; Cai Y
Oncol Rep; 2018 Aug; 40(2):1055-1063. PubMed ID: 29901161
[TBL] [Abstract][Full Text] [Related]
4. Dual agent loaded PLGA nanoparticles enhanced antitumor activity in a multidrug-resistant breast tumor eenograft model.
Chen Y; Zheng XL; Fang DL; Yang Y; Zhang JK; Li HL; Xu B; Lei Y; Ren K; Song XR
Int J Mol Sci; 2014 Feb; 15(2):2761-72. PubMed ID: 24552875
[TBL] [Abstract][Full Text] [Related]
5. Psoralen-loaded lipid-polymer hybrid nanoparticles enhance doxorubicin efficacy in multidrug-resistant HepG2 cells.
Yuan Y; Cai T; Callaghan R; Li Q; Huang Y; Wang B; Huang Q; Du M; Ma Q; Chiba P; Cai Y
Int J Nanomedicine; 2019; 14():2207-2218. PubMed ID: 30988617
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer.
Cheng X; Li D; Sun M; He L; Zheng Y; Wang X; Tang R
Colloids Surf B Biointerfaces; 2019 Sep; 181():185-197. PubMed ID: 31132609
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
8. Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies.
Li B; Xu H; Li Z; Yao M; Xie M; Shen H; Shen S; Wang X; Jin Y
Int J Nanomedicine; 2012; 7():187-97. PubMed ID: 22275834
[TBL] [Abstract][Full Text] [Related]
9. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
[TBL] [Abstract][Full Text] [Related]
10. Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells.
Zhang X; Li F; Guo S; Chen X; Wang X; Li J; Gan Y
Biomaterials; 2014 Apr; 35(11):3650-65. PubMed ID: 24462359
[TBL] [Abstract][Full Text] [Related]
11. Quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles for minimizing drug resistance in breast cancer.
Lv L; Liu C; Chen C; Yu X; Chen G; Shi Y; Qin F; Ou J; Qiu K; Li G
Oncotarget; 2016 May; 7(22):32184-99. PubMed ID: 27058756
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging.
Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y
J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307
[TBL] [Abstract][Full Text] [Related]
13. Psoralen reverses the P-glycoprotein-mediated multidrug resistance in human breast cancer MCF-7/ADR cells.
Jiang J; Wang X; Cheng K; Zhao W; Hua Y; Xu C; Yang Z
Mol Med Rep; 2016 Jun; 13(6):4745-50. PubMed ID: 27082231
[TBL] [Abstract][Full Text] [Related]
14. Co-delivery of docetaxel and Poloxamer 235 by PLGA-TPGS nanoparticles for breast cancer treatment.
Tang X; Liang Y; Feng X; Zhang R; Jin X; Sun L
Mater Sci Eng C Mater Biol Appl; 2015 Apr; 49():348-355. PubMed ID: 25686959
[TBL] [Abstract][Full Text] [Related]
15. Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy.
Li X; Jia X; Niu H
Int J Nanomedicine; 2018; 13():4107-4119. PubMed ID: 30034236
[TBL] [Abstract][Full Text] [Related]
16. PLGA nanoparticle formulation of RK-33: an RNA helicase inhibitor against DDX3.
Bol GM; Khan R; Heerma van Voss MR; Tantravedi S; Korz D; Kato Y; Raman V
Cancer Chemother Pharmacol; 2015 Oct; 76(4):821-7. PubMed ID: 26330329
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of rapamycin- and piperine-loaded polymeric nanoparticles for breast cancer treatment.
Katiyar SS; Muntimadugu E; Rafeeqi TA; Domb AJ; Khan W
Drug Deliv; 2016 Sep; 23(7):2608-2616. PubMed ID: 26036652
[TBL] [Abstract][Full Text] [Related]
18. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin.
Qiu L; Qiao M; Chen Q; Tian C; Long M; Wang M; Li Z; Hu W; Li G; Cheng L; Cheng L; Hu H; Zhao X; Chen D
Biomaterials; 2014 Dec; 35(37):9877-9887. PubMed ID: 25201738
[TBL] [Abstract][Full Text] [Related]
19. A glutathione-responsive sulfur dioxide polymer prodrug as a nanocarrier for combating drug-resistance in cancer chemotherapy.
Shen W; Liu W; Yang H; Zhang P; Xiao C; Chen X
Biomaterials; 2018 Sep; 178():706-719. PubMed ID: 29433753
[TBL] [Abstract][Full Text] [Related]
20. A polypeptide based podophyllotoxin conjugate for the treatment of multi drug resistant breast cancer with enhanced efficiency and minimal toxicity.
Zhou H; Lv S; Zhang D; Deng M; Zhang X; Tang Z; Chen X
Acta Biomater; 2018 Jun; 73():388-399. PubMed ID: 29694920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
